Oppenheimer & Co’s VanEck Biotech ETF BBH Stock Holding History

Oppenheimer & Co’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,290	Closed	-$202K	–	1577
2024 Q4	$202K	Sell	1,290 -40	-3%	-$6.73K	﹤0.01%	1453
2024 Q3	$236K	Hold	1,330	–	–	﹤0.01%	1343
2024 Q2	$224K	Buy	1,330 +10	+0.8%	+$1.64K	﹤0.01%	1305
2024 Q1	$220K	Buy	1,320 +20	+2%	+$3.31K	﹤0.01%	1301
2023 Q4	$215K	Sell	1,300 -750	-37%	-$115K	﹤0.01%	1261
2023 Q3	$319K	Sell	2,050 -500	-20%	-$79.9K	0.01%	1108
2023 Q2	$398K	Sell	2,550 -165	-6%	-$26.4K	0.01%	1054
2023 Q1	$440K	Buy	2,715 +30	+1%	+$4.85K	0.01%	993
2022 Q4	$429K	Buy	2,685 +280	+12%	+$44.4K	0.01%	966
2022 Q3	$339K	Sell	2,405 -180	-7%	-$27.2K	0.01%	1024
2022 Q2	$377K	Buy	+2,585	New	+$385K	0.01%	1022

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Oppenheimer & Co's BBH Position: Q1 2025 in Review

Oppenheimer & Co sold out of VanEck Biotech ETF (BBH) in Q1 2025, closing a stake of 1,290 shares — an estimated $202K sold.

Oppenheimer & Co first reported a position in BBH in Q2 2022 and held it in 11 quarters. The position peaked at $440K in Q1 2023. 104 funds tracked by Wall St. Rank hold BBH as of Q1 2025.

Oppenheimer & Co reported no remaining VanEck Biotech ETF position as of Q1 2025 after selling out during the quarter.
Oppenheimer & Co sold 1,290 VanEck Biotech ETF shares in Q1 2025, an estimated $202K.
Oppenheimer & Co first reported a position in VanEck Biotech ETF in Q2 2022 and held it in 11 quarters.
Oppenheimer & Co's VanEck Biotech ETF position peaked at $440K in Q1 2023.
104 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2025.

Based on Oppenheimer & Co's 13F filing for Q1 2025, filed 23 Apr 2025.